Sanofi — Director's Dealing 2019

Jul 23, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Fulcrum Therapeutics, Inc. (FULC)
CIK: 0001680581
Period of Report: 2019-07-22

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-07-22	Common Stock (par value $0.001)	C	464285	$0.00	Acquired	464285	Indirect
2019-07-22	Common Stock (par value $0.001)	P	93750	$16.00	Acquired	558035	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-22	Series B Preferred Stock (par value $0.001)	$0.00	C	3250000	Disposed		Common Stock (464285)	Indirect

Footnotes

F1: On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC.

F2: The reporting person acquired additional shares in the Issuer's initial public offering.